XM does not provide services to residents of the United States of America.
M
M

McKesson

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Costco Wholesale, McKesson, Starbucks

CORRECTED-U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE, the same error was there in a previous version of the U.S. research roundup Sept 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Costco Wholesale, McKesson and Starbucks, on Tuesday.
C
R
S
M
C
L

Costco Wholesale, McKesson, Starbucks

CORRECTED-US RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE; a previous version was corrected to fix headline tag to US RESEARCH ROUNDUP from EUROPE RESEARCH ROUNDUP and to change media packaging code to RESEARCH-US/ Sept 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Costco Wholesale, McKesson and Starbucks on Tuesday.
C
S
M
C
L

Cardinal Health to acquire Integrated Oncology Network for $1.12 billion

UPDATE 2-Cardinal Health to acquire Integrated Oncology Network for $1.12 billion Adds details and background throughout Sept 20 (Reuters) - Cardinal Health CAH.N on Friday agreed to acquire community cancer center operator Integrated Oncology Network for $1.12 billion in cash, marking its expansion into cancer care. The Dublin, Ohio-based company is the latest to join the trend of healthcare service companies diversifying beyond drug distribution.
M

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore to take drug distributors to trial over opioids

CORRECTED-Baltimore to take drug distributors to trial over opioids Corrects headline and lead, adds paragraphs 4-5 to state that J&J settled before trial By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.